Replies to post #113044 on Biotech Values

[flatlander_60048]

Agreed.

I wish I could remember or locate the article downplaying the commercial potential of everolimous. I can't recall the articles reason for dismissing the potential for this class of drugs. In any case, in addition to the stent coating, renal cancer and large cell cancer indications for which it is approved, NVS has indicated that there are approximately a half dozen clinical trials to evaluate further uses. In a sense these m-Tor inhibitors seem to possess the potential to act as a pipeline in a single drug. For this reason, I suspect we will see a lot of other firms pursuing similar drugs.

FL